daclatasvir

Daclatasvir (USAN, formerly BMS-790052, trade name Daklinza) is a drug for the treatment of hepatitis C (HCV). It was developed by Bristol-Myers Squibb and was approved in Europe on 22 August 2014. Daklinza gained its FDA approval on July 24, 2015 in the United States; it is approved for Hepatitis C genotype 3 infections.
Daclatasvir inhibits the HCV nonstructural protein NS5A. Recent research suggests that it targets two steps of the viral replication process, enabling rapid decline of HCV RNA.
Daclatasvir has been tested in combination regimens with pegylated interferon and ribavirin, as well as with other direct-acting antiviral agents including asunaprevir and sofosbuvir.
It is on the World Health Organization's List of Essential Medicines, a list of the most important medications needed in a basic health system.
There has been significant controversy over the price that Bristol-Myers Squibb has chosen to charge for the drug. As of December 2015 it cost between $50,000 – $84,000 in high-income countries.
In Bangladesh, Beacon Pharmaceuticals also produced a generic version product of Daclatasvir under the trade name of Daclavir in October 2015. Beacon also introduced a new combination Sofosbuvir/Daclatasvir under the brand name of Darvoni. Beacon got approval in January 2016 from the Directorate General of Drug Administration, Ministry of Health and Family Welfare, People's Republic of Bangladesh.
A generic version of daclatasvir was approved in India in December 2015 and is currently being sold under brand names NATDAC (produced by Natco Pharma) and MyDacla (produced by Mylan)